Sarcoma Research Goals
The ultimate goal of the Sarcoma or Liposcarcoma research is to help speed promising new drugs through the clinical trial process into clinical use. Currently, there are no effective drugs available for the treatment of Sarcoma or Liposcarcoma that cannot be cured by surgery—which may ultimately include most patients with this disease. Drug development requires basic science research to understand the underlying biology and genetics of the disease, identification of promising therapeutic targets, development of drugs that hit those targets, laboratory research using animals and cells in culture, clinical trials in humans proving benefit, and obtaining regulatory approval to market the drug. Drug development is an extremely expensive undertaking, often costing in the hundreds of millions of dollars.
The success of this process depends on significant basic science research and continues with translational research in which the results of work done in the laboratory are used to develop new ways to diagnose, prognose and treat the disease, including drugs which are ultimately evaluated via clinical trials for their efficacy. Collaborative research linking the laboratory to the clinic is critical. We cannot emphasize enough the benefit of bringing skilled physicians and scientists together to focus on translating science into the clinic, to help reduce the time required for drug development.
Such research is also expensive. Whole-genome (deep) sequencing has radically transformed our ability to decode cancer genomes. Deep sequencing of cancer tissues, which is vital to identifying the weaknesses in any cancer, requires significant investment. It currently costs $25,000 to sequence a single sample, from data generation to detailed bioinformatics analysis. Science requires many samples to reliably and reproducibly identify potential therapeutic targets for drug development.
The funds we are requesting will be used to help grow the teams of physicians and scientists already working on LSSI-funded Sarcoma research, and to extend the range of basic and translational science issues that they are investigating, including deep sequencing studies and bioinformatics studies. We require $50,000 to support a single researcher undertaking a basic science study for one year and $100,000 for two years. Collaborative research requires funding of at least $250,000 for 2-years.